What smart money is saying about Jiangsu Hengrui Pharmaceuticals
1 fund in our archive has pitched Jiangsu Hengrui Pharmaceuticals — most recently Alger International Opportunities Fund in December 2025.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Fund coverage · 1 thesis
- Alger International Opportunities FundDecember 2025
Jiangsu Hengrui Pharmaceuticals is pivoting toward innovative drugs and a global pipeline supported by international trials and partnerships despite timing-related earnings volatility.
Read the full thesis
Read every full thesis on Jiangsu Hengrui Pharmaceuticals
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→